Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cell-mediated Immune Response Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

NCT00311727
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Baltimore, Maryland • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Jul 22, 2026, 6:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccine in Pediatric Transplant Subjects

NCT00133510
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Subviron Influenza vaccine (Fluzone)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jul 22, 2026, 6:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

T and B Cell Responses in Autoimmune Diseases

NCT01947036
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jul 22, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

NCT04150913
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
Interventions
Anakinra, Axicabtagene Ciloleucel
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cytomegalovirus Cell-Mediated Immunity

NCT00815165
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 17 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Jul 22, 2026, 6:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Performance Comparison of QuantiFERON Monitor in Solid Organ Transplant Recipients

NCT02416414
View directory record Official record
Conditions
Cell-mediated Immune Response
Interventions
QuantiFERON Monitor Assay, Existing methodology
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Jul 22, 2026, 6:08 AM EDT
Active, not recruiting No phase listed Observational

A Longitudinal Study of COVID-19 Sequelae and Immunity

NCT04411147
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 6:08 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Pembroke Pines, Florida • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis

NCT00970749
View directory record Official record
Conditions
Chlamydia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Jul 22, 2026, 6:08 AM EDT
Completed Phase 1 Interventional

Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection

NCT00001763
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers

NCT00027482
View directory record Official record
Conditions
Healthy, HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 6:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cell Mediated Immunity in Older Adults

NCT01189123
View directory record Official record
Conditions
Immunity to Influenza Vaccine
Interventions
High dose influenza vaccine Sanofi-Pasteur, fluzone by sanofi pasteur
Biological
Lead sponsor
Vanderbilt University
Other
Eligibility
65 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Jul 22, 2026, 6:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

NK Cell Mediated Influenza Immunity During Pregnancy

NCT03196245
View directory record Official record
Conditions
Pregnancy Related, Influenza, Human
Interventions
There is no intervention.
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

NCT01558037
View directory record Official record
Conditions
Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Michael Ison
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine

NCT01288014
View directory record Official record
Conditions
Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
60 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational

Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases

NCT00357071
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 22, 2026, 6:08 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

NCT06853223
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 22, 2026, 6:08 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

NCT01248455
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
Interventions
(Anti-KIR)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 22, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

NCT03746015
View directory record Official record
Conditions
Dengue Fever
Interventions
TDV
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Peoria, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 22, 2026, 6:08 AM EDT
Not listed Not applicable Interventional

Immunogenicity of Influenza Vaccine in Long Term Care

NCT02933723
View directory record Official record
Conditions
Influenza
Interventions
Blood Draw
Procedure
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction

NCT00001531
View directory record Official record
Conditions
Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

NCT05089565
View directory record Official record
Conditions
Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
Interventions
Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jul 22, 2026, 6:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

NCT05898828
View directory record Official record
Conditions
Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm, Esophagus Cancer, Neoplasms, Esophageal, Esophageal Cancer (EsC)
Interventions
Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant, H1299 Cell Lysates
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Jul 22, 2026, 6:08 AM EDT